BTEC:SW:SW-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD (USD)

ETF | Others |

Last Closing

USD 6.49

Change

0.00 (0.00)%

Market Cap

USD 0.52B

Volume

1.46K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.03 (+0.20%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.06 (-0.29%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.01 (-0.02%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

-24.00 (-0.30%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+20.00 (+0.37%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+7.60 (+0.46%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+29.00 (+1.35%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.22 (+0.29%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+0.10 (+0.09%)

USD 130,595.12B

ETFs Containing BTEC:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.64% 25% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.64% 25% F 27% F
Trailing 12 Months  
Capital Gain 12.23% 53% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.23% 52% F 55% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.05% 46% F 47% F
Dividend Return 2.05% 46% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 3.71% 71% C- 74% C
Risk Adjusted Return 55.14% 53% F 57% F
Market Capitalization 0.52B 64% D 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.